Drug Development

Drug Development

Developing Drugs Able to Treat Neurological Disease – Boston Biotech Clinical Research

June 30th, 2020 | Drug Development

Techniques that bypass or trick the guardian of the central nervous system. Developing drugs that can penetrate into the brain requires some creativity. The approaches vary, each technique comes with its benefits and drawbacks, making it appropriate for some patients or drug types but not others. In some diseases, you might want the drug everywhere; […]

2019 Successful Clinical Plan and Drug Development Stories

January 27th, 2020 | Drug Development

Gene therapies for disorders such as X-linked Severe Combined Immunodeficiency (SCID, sometimes known as “bubble boy disease”), and Spinal Muscular Atrophy (SMA) have, for the first time, shown remarkable safety and efficacy results in clinical trials. FDA approved Trikafta, a gene-based therapy creating hope for children with cystic fibrosis and Zolgensma, a gene therapy drug, […]

The BBCR team designs Proof of Concept (PoC) Trials and Proof of Mechanism (PoM) studies with the drug clinical plan and regulatory strategy in mind.

December 19th, 2019 | Drug Development

Proof of Mechanism (PoM) Usually in Healthy Volunteers, Phase 1 study Essential for the selection of appropriate dose for PoC, disease model and biomarkers Investigate drug concentration at the target site of action Investigate drug engagement with target molecular receptor or enzyme (e.g. Receptor binding Investigate if drug biological response after target binding match the […]

Cost vs. Value: Can We Have Both?

August 1st, 2019 | Drug Development

Could Seamless Adaptive Designs Advance Rare Disease Clinical Trial Design?

July 24th, 2019 | Drug Development

Strategic Consulting: The convergence revolution to innovate clinical trial process

May 10th, 2019 | Drug Development

Strategic Consulting – SCIO Process -A New Way for Drug Development

April 30th, 2019 | Drug Development

Pin It on Pinterest